Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1

Vaccine

Volumn 28, Issue 42, 2010, Pages 6901-6914

  Gwinn, William M ^a   Kirwan, Shaun M ^a   Wang, Sheena H ^b   Ashcraft, Kathleen A ^a   Sparks, Neil L ^a   Doil, Catherine R ^a   Tlusty, Tom G ^a   Casey, Leslie S ^c,e   Hollingshead, Susan K ^d   Briles, David E ^d   Dondero, Richard S ^c,f   Hickey, Anthony J ^b   Foster, W Michael ^a   Staats, Herman F ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b University of North Carolina   (United States)

^c Cistron Biotechnology   (United States)

^d University of Alabama at Birmingham   (United States)

^e Elusys Therapeutics Inc   (United States)

^f Senesco Technologies Inc   (United States)

Author keywords

Adjuvant; Interleukin 1; Nasal

Indexed keywords

ALUMINUM POTASSIUM SULFATE; ANTIGEN; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 1BETA; PNEUMOCOCCAL SURFACE PROTEIN A; RECOMBINANT ANTIGEN; RECOMBINANT PROTECTIVE ANTIGEN; TETANUS TOXOID; TOXIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; COLLOID; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GAMMA SCINTIGRAPHY; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; ISOTOPE LABELING; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BACTERIAL TOXINS; BACTERIAL VACCINES; FEMALE; IMMUNIZATION; IMMUNOGLOBULIN G; INTERLEUKIN-1ALPHA; INTERLEUKIN-1BETA; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; RABBITS; RADIONUCLIDE IMAGING; STREPTOCOCCUS PNEUMONIAE; TETANUS TOXOID;

EID: 77956882975     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.08.006     Document Type: Article

References (95)

1. Giudice E.L., Campbell J.D. Needle-free vaccine delivery. Adv Drug Deliv Rev 2006, 58(April (1)):68-89.
2. Clements C.J., Larsen G., Jodar L. Technologies that make administration of vaccines safer. Vaccine 2004, 22(May (15-16)):2054-2058.
3. Clements C.J., Aguado M.T., Jodar L. Technologies to improve immunisation safety. Drug Saf 2001, 24(14):1019-1026.
4. Levine M.M. Can needle-free administration of vaccines become the norm in global immunization?. Nat Med 2003, 9(1):99.
5. Brody S. Declining HIV rates in Uganda: due to cleaner needles, not abstinence or condoms. Int J STD AIDS 2004, 15(July (7)):440-441.
6. Simonsen L., Kane A., Lloyd J., Zaffran M., Kane M. Unsafe injections in the developing world and transmission of bloodborne pathogens: a review. Bull World Health Org 1999, 77(10):789-800.
7. Baillie L.W. Past, imminent and future human medical countermeasures for anthrax. J Appl Microbiol 2006, 101(September (3)):594-606.
8. O'Hagan D.T., Rappuoli R. Novel approaches to vaccine delivery. Pharm Res 2004, 21(September (9)):1519-1530.
9. Kersten G., Hirschberg H. Needle-free vaccine delivery. Exp Opin Drug Deliv 2007, 4(September (5)):459-474.
10. Boivin J.M., Poupon-Lemarquis L., Iraqi W., Fay R., Schmitt C., Rossignol P. A multifactorial strategy of pain management is associated with less pain in scheduled vaccination of children. A study realized by family practitioners in 239 children aged 4-12 years old. Fam Pract 2008, 25(December (6)):423-429.
11. Williams J.P., Lednar W. New developments in influenza vaccine technology: a potential new prevention strategy for employers and managed care organizations. Am J Manag Care 2002, 8(April (Suppl. 5)):S143-S154.
12. Aggerbeck H., Gizurarson S., Wantzin J., Heron I. Intranasal booster vaccination against diphtheria and tetanus in man. Vaccine 1997, 15(3):307-316.
13. McSherry J. Perspectives on needle phobia. J Fam Pract 1995, 41(5):437. 512.
14. Hamilton J.G. Needle phobia: a neglected diagnosis. J Fam Pract 1995, 41(2):169-175.
15. FDA News First nasal mist flu vaccine approved 2003, Available from: http://www.fda.gov/bbs/topics/NEWS/2003/NEW00913.html [cited June 17, 2003].
16. McCarthy M.W., Kockler D.R. Trivalent intranasal influenza vaccine, live. Ann Pharmacother 2004, 38(December (12)):2086-2093.
17. Belshe R.B., Nichol K.L., Black S.B., Shinefield H., Cordova J., Walker R., et al. Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5-49 years. Clin Infect Dis 2004, 39(October (7)):920-927.
18. Staats H.F., Jackson R.J., Marinaro M., Takahashi I., Kiyono H., McGhee J.R. Mucosal immunity to infection with implications for vaccine development. Curr Opin Immunol 1994, 6(August (4)):572-583.
19. Neutra M.R., Kozlowski P.A. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006, 6(2):148.
20. Prakken B.J., van der Zee R., Anderton S.M., van Kooten P.J.S., Kuis W., Eden W.V. Peptide-induced nasal tolerance for a mycobacterial heat shock protein 60 T cell epitope in rats suppresses both adjuvant arthritis and nonmicrobially induced experimental arthritis. Proc Natl Acad Sci USA 1997, 94:3284-3289.
21. Staines N.A., Harper N., Ward F.J., Malmstrom V., Holmdahl R., Bansal S. Mucosal tolerance and suppression of collagen-induced arthritis (CIA) induced by nasal administration of synthetic peptide 184-198 of bovine type II collagen (CII) expressing a dominant T cell epitope. Clin Exp Immunol 1996, 103:368-375.
22. Xiao B.G., Link H. Mucosal tolerance: a two-edged sword to prevent and treat autoimmune diseases. Clin Immunol Immunopathol 1997, 85(2):119-128.
23. Bai X.F., Shi F.D., Xiao B.G., Li H.L., van der Meide P.H., Link H. Nasal administration of myelin basic protein prevents relapsing experimental autoimmune encephalomyelitis in DA rats by activating regulatory cells expressing IL-4 and TGF-beta mRNA. J Neuroimmunol 1997, 80(1-2):65-75.
24. Zhu J., Deng G.M., Levi M., Wahren B., Diab A., Vandermeide P.H., et al. Prevention of experimental autoimmune neuritis by nasal administration of P2 protein peptide 57-81. J Neuropathol Exp Neurol 1998, 57(3):291-301.
25. Hasselberg A., Ekman L., Yrlid L.F., Schon K., Lycke N.Y. ADP-ribosylation controls the outcome of tolerance or enhanced priming following mucosal immunization. J Immunol 2010, 184(March (6)):2776-2784.
26. Milling S.W., Yrlid U., Jenkins C., Richards C.M., Williams N.A., MacPherson G. Regulation of intestinal immunity: effects of the oral adjuvant Escherichia coli heat-labile enterotoxin on migrating dendritic cells. Eur J Immunol 2007, 37(January (1)):87-99.
27. Chabot S., Wagner J.S., Farrant S., Neutra M.R. TLRs regulate the gatekeeping functions of the intestinal follicle-associated epithelium. J Immunol 2006, 176(April (7)):4275-4283.
28. Lycke N. From toxin to adjuvant: basic mechanisms for the control of mucosal IgA immunity and tolerance. Immunol Lett 2005, 97(March (2)):193-198.
29. Lycke N. ADP-ribosylating bacterial enzymes for the targeted control of mucosal tolerance and immunity. Ann N Y Acad Sci 2004, December (1029):193-208.
30. Snider D.P., Marshall J.S., Perdue M.H., Liang H. Production of IgE antibody and allergic sensitization of intestinal and peripheral tissues after oral immunization with protein Ag and cholera toxin. J Immunol 1994, 153(2):647-657.
31. van Ginkel F.W., Jackson R.J., Yuki Y., McGhee J.R. Cutting Edge: The mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J Immunol 2000, 165:4778-4782.
32. Marinaro M., Staats H.F., Hiroi T., Jackson R.J., Coste M., Boyaka P.N., et al. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. J Immunol 1995, 155(November (10)):4621-4629.
33. Simecka J.W., Jackson R.J., Kiyono H., McGhee J.R. Mucosally induced immunoglobulin E-associated inflammation in the respiratory tract. Infect Immun 2000, 68(February (2)):672-679.
34. Couch R.B. Nasal vaccination, Escherichia coli enterotoxin, and Bell's palsy. N Engl J Med 2004, 350(9):860-861. [comment].
35. Mutsch M., Zhou W., Rhodes P., Bopp M., Chen R.T., Linder T., et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 2004, 350(9):896-903. [see comment].
36. Lewis D.J., Huo Z., Barnett S., Kromann I., Giemza R., Galiza E., et al. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS One 2009, 4(9):e6999.
37. Staats H.F., Ennis F.A. IL-1 is an effective adjuvant for mucosal and systemic immune responses when coadministered with protein immunogens. J Immunol 1999, 162(May (10)):6141-6147.
38. Bradney C.P., Sempowski G.D., Liao H.X., Haynes B.F., Staats H.F. Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization. J Virol 2002, 76(January (2)):517-524.
39. Wu H.Y., Nguyen H.H., Russell M.W. Nasal lymphoid tissue (NALT) as a mucosal immune inductive site. Scan J Immunol 1997, 46(5):506-513.
40. Wu H.Y., Russell M.W. Nasal lymphoid tissue, intranasal immunization, and compartmentalization of the common mucosal immune system. Immunol Res 1997, 16(2):187-201.
41. Zuercher A.W., Cebra J.J. Structural and functional differences between putative mucosal inductive sites of the rat. Eur J Immunol 2002, 32(11):3191-3196.
42. Bienenstock J., McDermott M.R. Bronchus- and nasal-associated lymphoid tissues. Immunol Rev 2005, 206(1):22-31.
43. Kiyono H., Fukuyama S. NALT- versus Peyer's-patch-mediated mucosal immunity. Nat Rev Immunol 2004, 4(September (9)):699-710.
44. Brandtzaeg P. Immunology of tonsils and adenoids: everything the ENT surgeon needs to know. Int J Pediatr Otorhinolaryngol 2003, 67(December (Suppl. 1)):S69-S76.
45. Boyaka P.N., Wright P.F., Marinaro M., Kiyono H., Johnson J.E., Gonzales R.A., et al. Human nasopharyngeal-associated lymphoreticular tissues. Functional analysis of subepithelial and intraepithelial B and T cells from adenoids and tonsils. Am J Pathol 2000, 157(December (6)):2023-2035.
46. Staats H.F., Nichols W.G., Palker T.J. Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A). J Immunol 1996, 157(July (1)):462-472.
47. Egan M.A., Chong S.Y., Hagen M., Megati S., Schadeck E.B., Piacente P., et al. A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques. Vaccine 2004, 22(27-28):3774-3788.
48. Janakova L., Bakke H., Haugen I.L., Berstad A.K., Hoiby E.A., Aaberge I.S., et al. Influence of intravenous anesthesia on mucosal and systemic antibody responses to nasal vaccines. Infect Immun 2002, 70(October (10)):5479-5484.
49. Sloat B.R., Cui Z. Evaluation of the immune response induced by a nasal anthrax vaccine based on the protective antigen protein in anaesthetized and non-anaesthetized mice. J Pharm Pharmacol 2006, 58(April (4)):439-447.
50. Southam D.S., Dolovich M., O'Byrne P.M., Inman M.D. Distribution of intranasal instillations in mice: effects of volume, time, body position, and anesthesia. Am J Physiol Lung Cell Mol Physiol 2002, 282(December (4)):L833-L839.
51. Matsuura S., Shirakami G., Iida H., Tanimoto K., Fukuda K. The effect of sevoflurane on ciliary motility in rat cultured tracheal epithelial cells: a comparison with isoflurane and halothane. Anesth Analg 2006, 102(June (6)):1703-1708.
52. Aucouturier J., Dupuis L., Deville S., Ascarateil S., Ganne V. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev Vaccines 2002, 1(June (1)):111-118.
53. Aucouturier J., Ascarateil S., Dupuis L. The use of oil adjuvants in therapeutic vaccines. Vaccine 2006, 24(April (Suppl. 2)). S2-44-5.
54. Aucouturier J., Dupuis L., Deville S., Ascarateil S., Ganne V. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Exp Rev Vaccines 2002, 1:111-118.
55. von Uexkull C., Nourshargh S., Williams T.J. Comparative responses of human and rabbit interleukin-1 in vivo: effect of a recombinant interleukin-1 receptor antagonist. Immunology 1992, 77(December (4)):483-487.
56. Vandenabeele P., Guisez Y., Declercq W., Bauw G., Vandekerckhove J., Fiers W. Response of murine cell lines to an IL-1/IL-2-induced factor in a rat/mouse T hybridoma (PC60): differential induction of cytokines by human IL-1 alpha and IL-1 beta and partial amino acid sequence of rat GM-CSF. Lymphokine Res 1990, 9(Fall (3)):381-389.
57. Libert C., Brouckaert P., Shaw A., Fiers W. Induction of interleukin 6 by human and murine recombinant interleukin 1 in mice. Eur J Immunol 1990, 20(March (3)):691-694.
58. Lederer J.A., Czuprynski C.J. Species-specific binding of IL-1, but not the IL-1 receptor antagonist, by fibroblasts. Cytokine 1994, 6(March (2)):154-161.
59. Kokuryo S., Inoue H., Fukuizumi T., Tsujisawa T., Tominaga K., Fukuda J. Evaluation of interleukin 1 as a mucosal adjuvant in immunization with Streptococcus sobrinus cells by tonsillar application in rabbits. Oral Microbiol Immunol 2002, 17(3):163-171.
60. Wagner E.M., Foster W.M. Importance of airway blood flow on particle clearance from the lung. J Appl Physiol 1996, 81(November (5)):1878-1883.
61. Lausch R.N., Staats H., Metcalf J.F., Oakes J.E. Effective antibody therapy in herpes simplex virus ocular infection. Characterization of recipient immune response. Intervirology 1990, 31:159-165.
62. Jackson R.J., Fujihashi K., Xu-Amano J., Kiyono H., Elson C.O., McGhee J.R. Optimizing oral vaccines: induction of systemic and mucosal B-cell and antibody responses to tetanus toxoid by use of cholera toxin as an adjuvant. Infect Immun 1993, 61(October (10)):4272-4279.
63. Yamamoto M., Briles D.E., Yamamoto S., Ohmura M., Kiyono H., McGhee J.R. A nontoxic adjuvant for mucosal immunity to pneumococcal surface protein A. J Immunol 1998, 161(October (8)):4115-4121.
64. Yamamoto M., McDaniel L.S., Kawabata K., Briles D.E., Jackson R.J., McGhee J.R., et al. Oral immunization with PspA elicits protective humoral immunity against Streptococcus pneumoniae infection. Infect Immun 1997, 65(2):640-644.
65. Swiatlo E., King J., Nabors G.S., Mathews B., Briles D.E. Pneumococcal surface protein a is expressed in vivo, and antibodies to PspA are effective for therapy in a murine model of pneumococcal sepsis. Infect Immun 2003, 71(12):7149-7153.
66. Little S.F., Ivins B.E., Fellows P.F., Pitt M.L.M., Norris S.L.W., Andrews G.P. Defining a serlogical correlate of protection in rabbits for a recombinant anthrax vaccine. Vaccine 2004, 22:422-430.
67. Atmar R.L., Keitel W.A., Cate T.R., Munoz F.M., Ruben F., Couch R.B. A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults. Vaccine 2007, 25(29):5367.
68. Mikszta J.A., Sullivan V.J., Dean C., Waterston A.M., Alarcon J.B., Dekker J.P., et al. Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms. J Infect Dis 2005, 191(January (2)):278-288.
69. Staats H.F., Montgomery S.P., Palker T.J. Intranasal immunization is superior to vaginal, gastric, or rectal immunization for the induction of systemic and mucosal anti-HIV antibody responses. AIDS Res Hum Retroviruses 1997, 13(July (11)):945-952.
70. McLachlan J.B., Shelburne C.P., Hart J.P., Pizzo S.V., Goyal R., Brooking-Dixon R., et al. Mast cell activators: a new class of highly effective vaccine adjuvants. Nat Med 2008, 14(May (5)):536-541.
71. Staats H.F., Alam S.M., Scearce R.M., Kirwan S.M., Zhang J.X., Gwinn W.M., et al. In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity. Infect Immun 2007, 75(November (11)):5443-5452.
72. Kouiavskaia D.V., Berard C.A., Datena E., Hussain A., Dawson N., Klyushnenkova E.N., et al. Vaccination with agonist peptide PSA: 154-163 (155L) derived from prostate specific antigen induced CD8 T-cell response to the native peptide PSA: 154-163 but failed to induce the reactivity against tumor targets expressing PSA: a phase 2 study in patients with recurrent prostate cancer. J Immunother 2009, 32(July-August (6)):655-666.
73. Wu Y., Ellis R.D., Shaffer D., Fontes E., Malkin E.M., Mahanty S., et al. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS One 2008, 3(7):e2636.
74. Harkema J.R., Carey S.A., Wagner J.G. The nose revisited: a brief review of the comparative structure, function, and toxicologic pathology of the nasal epithelium. Toxicol Pathol 2006, 34(3):252-269.
75. Casteleyn C., Broos A.M., Simoens P., Van den Broeck W. NALT (nasal cavity-associated lymphoid tissue) in the rabbit. Vet Immunol Immunopathol 2010, 133(February (2-4)):212-218.
76. Park C.Y., Jung S.H., Bak J.P., Lee S.S., Rhee D.K. Comparison of the rabbit pyrogen test and Limulus amoebocyte lysate (LAL) assay for endotoxin in hepatitis B vaccines and the effect of aluminum hydroxide. Biologicals 2005, 33(September (3)):145-151.
77. Nakagawa Y., Maeda H., Murai T. Evaluation of the in vitro pyrogen test system based on proinflammatory cytokine release from human monocytes: comparison with a human whole blood culture test system and with the rabbit pyrogen test. Clin Diagn Lab Immunol 2002, 9(May (3)):588-597.
78. Spreitzer I., Fischer M., Hartzsch K., Luderitz-Puchel U., Montag T. Comparative study of rabbit pyrogen test and human whole blood assay on human serum albumin. Altex 2002, 19(Suppl. 1):73-75.
79. Lofthouse S.A., Andrews A.E., Barcham G.J., Nash A.D. Parameters related to the application of recombinant ovine interleukin-1 beta as an adjuvant. Vaccine 1995, 13(14):1277-1287.
80. Staruch M.J., Wood D.D. The adjuvanticity of interleukin 1 in vivo. J Immunol 1983, 130(5):2191-2194.
81. Dinarello C.A. Cytokines as endogenous pyrogens. J Infect Dis 1999, 179(Suppl. 2):S294-S304.
82. Wimer-Mackin S., Hinchcliffe M., Petrie C.R., Warwood S.J., Tino W.T., Williams M.S., et al. An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits. Vaccine 2006, 24(18):3953-3963.
83. Garmise R.J., Staats H.F., Hickey A.J. Novel dry powder preparations of whole inactivated influenza virus for nasal vaccination. AAPS PharmSciTech 2007, 8(4):E81.
84. Bryant M.L., Brown P., Gurevich N., McDougall I.R. Comparison of the clearance of radiolabelled nose drops and nasal spray as mucosally delivered vaccine. Nucl Med Commun 1999, 20(2):171-174.
85. Brandtzaeg P. Induction of secretory immunity and memory at mucosal surfaces. Vaccine 2007, 25(July (30)):5467-5484.
86. Huang J., Mikszta J.A., Ferriter M.S., Jiang G., Harvey N.G., Dyas B., et al. Intranasal administration of dry powder anthrax vaccine provides protection against lethal aerosol spore challenge. Hum Vaccines 2007, 3(May-June (3)):90-93.
87. Coucke D., Schotsaert M., Libert C., Pringels E., Vervaet C., Foreman P., et al. Spray-dried powders of starch and crosslinked poly(acrylic acid) as carriers for nasal delivery of inactivated influenza vaccine. Vaccine 2009, 27(February (8)):1279-1286.
88. Boyaka P.N., Tafaro A., Fischer R., Leppla S.H., Fujihashi K., McGhee J.R. Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen. J Immunol 2003, 170(June (11)):5636-5643.
89. Veltri S., Smith J.W. Interleukin 1 trials in cancer patients: a review of the toxicity, antitumor and hematopoietic effects. Stem Cells 1996, 14(2):164-176.
90. Hashimoto M., Ishikawa Y., Yokota S., Goto F., Bando T., Sakakibara Y., et al. Action site of circulating interleukin-1 on the rabbit brain. Brain Res 1991, 540(1-2):217-223.
91. Murakami N., Sakata Y., Watanabe T. Central action sites of interleukin-1 beta for inducing fever in rabbits. J Physiol 1990, 428:299-312.
92. Jaganathan K.S., Vyas S.P. Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally. Vaccine 2006, 24(May (19)):4201-4211.
93. Soane R.J., Hinchcliffe M., Davis S.S., Illum L. Clearance characteristics of chitosan based formulations in the sheep nasal cavity. Int J Pharm 2001, 217(1-2):183-191.
94. Cox R.J., Brokstad K.A., Ogra P. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol 2004, 59(1):1-15.
95. Beyer W.E., Palache A.M., de Jong J.C., Osterhaus A.D. Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. Vaccine 2002, 20(9-10):1340-1353. [see comment].